In Brief: St. Jude
This article was originally published in The Gray Sheet
St. Jude: St. Paul, Minnesota-based firm organizing tachycardia personnel and resources under the leadership of Mark Kroll, PhD, former VP Research and Product Planning at Minneapolis-based Angeion Corporation, who is appointed VP of the new St. Jude tachycardia division. St. Jude plans to form an advanced tachycardia research team in Minnesota to further its platform tachycardia technology; the firm holds rights to the technology through ongoing cross-patent and technology licensing agreements with Angeion. The firm also holds a worldwide distribution agreement to sell Angeion's Sentinel 2000 and 2001 implantable cardiac defibrillator models under a Pacesetter tradename. St. Jude expects the first implant of the ICD to occur in early 1996, according to an Oct. 31 release. In a separate release, Angeion reports that it received FDA approval to begin its own clinical trials in the U.S. for the Sentinel 2000 defibrillation system...
You may also be interested in...
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.